Top Drug Discovery Startups in 2026

Reify Health provides cloud-based software that accelerates development of new and life-saving therapies. We serve the global life science industry, including thousands of clinical research sites, the most innovative biotechs, and the world’s largest biopharmaceutical companies. Our global healthcare system relies on clinical trials to develop new, life-saving treatments for patients. But clinical trials continue to be slow, unpredictable, and expensive. Reify Health’s StudyTeam clinical trial software empowers both the research sponsors who drive clinical trials forward and the doctors and research coordinators who care for patient volunteers so that they can devote more focus and time toward the work that results in successful clinical research.

Our mission is to harness advanced technologies to increase our understanding of the biology that underlies lifespan, and to seek interventions that enable people to lead longer and healthier lives. We bring together scientists and technologists, thinkers and tinkerers, to explore the fundamental biology of aging. At Calico, you'll work closely with scientists to help ask big scientific questions, and invent software to help answer them. We're part of the Alphabet family, which includes Google, Verily, Waymo, and other companies.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space. The Schrödinger platform is deployed by industry leaders worldwide for drug discovery, as well as for materials science in fields as diverse as aerospace, energy, semiconductors, oil and gas, automotive, and electronics displays. The platform also powers our own drug discovery efforts, from target identification to hit discovery to lead optimization. It also drives our research collaborations to develop novel medicines for critical public health needs. With more than 150 Ph.D. scientists on our team, we invest heavily in R&D. We’ve published over 400 peer-reviewed papers that demonstrate the strength of our physics-based approaches, and we’re continually pushing the limits of computer modeling.

90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.

Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.